AU2001272262A1 - Drug delivery system for poorly water soluble drugs - Google Patents
Drug delivery system for poorly water soluble drugsInfo
- Publication number
- AU2001272262A1 AU2001272262A1 AU2001272262A AU7226201A AU2001272262A1 AU 2001272262 A1 AU2001272262 A1 AU 2001272262A1 AU 2001272262 A AU2001272262 A AU 2001272262A AU 7226201 A AU7226201 A AU 7226201A AU 2001272262 A1 AU2001272262 A1 AU 2001272262A1
- Authority
- AU
- Australia
- Prior art keywords
- chitosan
- drug
- hydrogel
- water soluble
- poorly water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 96
- 239000003814 drug Substances 0.000 title claims abstract description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000012377 drug delivery Methods 0.000 title claims description 11
- 239000000017 hydrogel Substances 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 50
- 238000005063 solubilization Methods 0.000 claims abstract description 11
- 230000007928 solubilization Effects 0.000 claims abstract description 11
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 57
- 229960002297 fenofibrate Drugs 0.000 claims description 56
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 46
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 41
- 229960001597 nifedipine Drugs 0.000 claims description 39
- 229920001661 Chitosan Polymers 0.000 claims description 38
- 229960000905 indomethacin Drugs 0.000 claims description 23
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 21
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 21
- 229960001661 ursodiol Drugs 0.000 claims description 21
- 239000006185 dispersion Substances 0.000 claims description 9
- 230000021736 acetylation Effects 0.000 claims description 7
- 238000006640 acetylation reaction Methods 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 28
- 230000008569 process Effects 0.000 abstract description 17
- 238000004090 dissolution Methods 0.000 description 57
- 238000007922 dissolution test Methods 0.000 description 22
- 239000012738 dissolution medium Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000008057 potassium phosphate buffer Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000363 spectroscopic quantification Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21662700P | 2000-07-07 | 2000-07-07 | |
| US60216627 | 2000-07-07 | ||
| US25238900P | 2000-11-21 | 2000-11-21 | |
| US60252389 | 2000-11-21 | ||
| PCT/CA2001/000993 WO2002003962A2 (fr) | 2000-07-07 | 2001-07-06 | Système d'apport de médicaments faiblement hydrosolubles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001272262A1 true AU2001272262A1 (en) | 2002-01-21 |
Family
ID=26911183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001272262A Abandoned AU2001272262A1 (en) | 2000-07-07 | 2001-07-06 | Drug delivery system for poorly water soluble drugs |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030157171A1 (fr) |
| EP (1) | EP1299089B1 (fr) |
| JP (1) | JP2004502722A (fr) |
| AT (1) | ATE322891T1 (fr) |
| AU (1) | AU2001272262A1 (fr) |
| BR (1) | BR0112258A (fr) |
| CA (1) | CA2415081A1 (fr) |
| DE (1) | DE60118742D1 (fr) |
| IL (1) | IL153814A0 (fr) |
| NO (1) | NO20030073L (fr) |
| NZ (1) | NZ523418A (fr) |
| WO (1) | WO2002003962A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050221501A1 (en) * | 2003-12-24 | 2005-10-06 | Arnot Kate I | Dissolution method |
| IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
| EP2074992B1 (fr) * | 2005-04-08 | 2015-05-20 | Abbott Laboratories | Formulations pharmaceutiques orales contenant des sels de l'acide fénofibrique |
| EP1928473A4 (fr) * | 2005-09-28 | 2009-11-18 | Dnp Canada Inc | Combinaison de polychitosamine et de fibrate pour prevenir et traiter l'hyperlipidemie |
| WO2007056205A2 (fr) * | 2005-11-04 | 2007-05-18 | Eastman Chemical Company | Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles |
| AU2007235322A1 (en) | 2006-04-05 | 2007-10-18 | Woodland Biofuels Inc. | System and method for converting biomass to ethanol via syngas |
| US20100129423A1 (en) * | 2007-04-19 | 2010-05-27 | Medovent Gmbh | Device made at least partially of n-acetylchitosan with controlled biodissolution |
| WO2012034079A2 (fr) | 2010-09-09 | 2012-03-15 | Micell Technologies, Inc. | Formes pharmaceutiques de type macrolides |
| WO2013018050A2 (fr) | 2011-08-01 | 2013-02-07 | Ranbaxy Laboratories Limited | Système d'administration de médicaments à libération contrôlée et dissolution améliorée pour médicaments peu solubles dans l'eau |
| CN103315960A (zh) * | 2012-03-19 | 2013-09-25 | 胡容峰 | 基于球晶技术固体自微乳及其制备方法 |
| US20200262937A1 (en) * | 2017-09-27 | 2020-08-20 | Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies (A4Tec)- | High molecular weight chitosan, process for obtaining and uses thereof |
| KR102407470B1 (ko) * | 2021-08-09 | 2022-06-10 | 인제대학교 산학협력단 | 하이드로겔에 담지된 약물의 방출량 검출 방법 |
| CN114515268B (zh) * | 2022-02-21 | 2024-06-21 | 上海宣泰医药科技股份有限公司 | 熊去氧胆酸药物组合物及其制备方法和药物制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620706A (en) * | 1995-04-10 | 1997-04-15 | Universite De Sherbrooke | Polyionic insoluble hydrogels comprising xanthan and chitosan |
| CA2243619A1 (fr) * | 1998-07-17 | 2000-01-17 | Universite De Sherbrooke | Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines |
-
2001
- 2001-07-06 US US10/332,251 patent/US20030157171A1/en not_active Abandoned
- 2001-07-06 IL IL15381401A patent/IL153814A0/xx unknown
- 2001-07-06 DE DE60118742T patent/DE60118742D1/de not_active Expired - Lifetime
- 2001-07-06 EP EP01951278A patent/EP1299089B1/fr not_active Expired - Lifetime
- 2001-07-06 AU AU2001272262A patent/AU2001272262A1/en not_active Abandoned
- 2001-07-06 BR BR0112258-4A patent/BR0112258A/pt not_active IP Right Cessation
- 2001-07-06 CA CA002415081A patent/CA2415081A1/fr not_active Abandoned
- 2001-07-06 WO PCT/CA2001/000993 patent/WO2002003962A2/fr not_active Ceased
- 2001-07-06 JP JP2002508417A patent/JP2004502722A/ja not_active Withdrawn
- 2001-07-06 NZ NZ523418A patent/NZ523418A/en unknown
- 2001-07-06 AT AT01951278T patent/ATE322891T1/de not_active IP Right Cessation
-
2003
- 2003-01-07 NO NO20030073A patent/NO20030073L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60118742D1 (de) | 2006-05-24 |
| IL153814A0 (en) | 2003-07-31 |
| ATE322891T1 (de) | 2006-04-15 |
| WO2002003962A3 (fr) | 2002-06-13 |
| WO2002003962A2 (fr) | 2002-01-17 |
| NZ523418A (en) | 2004-09-24 |
| US20030157171A1 (en) | 2003-08-21 |
| NO20030073D0 (no) | 2003-01-07 |
| NO20030073L (no) | 2003-03-06 |
| EP1299089B1 (fr) | 2006-04-12 |
| JP2004502722A (ja) | 2004-01-29 |
| BR0112258A (pt) | 2003-06-24 |
| EP1299089A2 (fr) | 2003-04-09 |
| CA2415081A1 (fr) | 2002-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs | |
| Shu et al. | Controlled drug release properties of ionically cross-linked chitosan beads: the influence of anion structure | |
| CA2666587C (fr) | Nanoparticules micellaires de substances chimiques | |
| Ganesan et al. | Development, characterization and solubility enhancement of comparative dissolution study of second generation of solid dispersions and microspheres for poorly water soluble drug | |
| EP1299089B1 (fr) | Systeme d'apport de medicaments faiblement hydrosolubles | |
| JP2007504266A (ja) | ジプラシドンの持続放出剤形 | |
| JP2005517690A (ja) | 固体薬物分散物を含有する即時放出剤形 | |
| JPH11507958A (ja) | 徐放性ヘテロ分散ヒドロゲル系―非晶薬物 | |
| US20020076444A1 (en) | Novel method for obtaining microspheres and resulting products | |
| Segale et al. | Calcium alginate multi-unit oral dosage form for delayed release of celecoxib | |
| Prado et al. | Basic butylated methacrylate copolymer/kappa-carrageenan interpolyelectrolyte complex: preparation, characterization and drug release behaviour | |
| TWI392507B (zh) | 包埋的膠束奈米顆粒 | |
| WO2021219808A1 (fr) | Formulations solides et liquisolides de la corallopyronine a | |
| Shikha et al. | Microfluidic Particle Engineering of Hydrophobic Drug with Eudragit E100─ Bridging the Amorphous and Crystalline Gap | |
| Krueger et al. | “MCC SANAQ® burst”—a new type of cellulose and its suitability to prepare fast disintegrating pellets | |
| Kunasekaran et al. | Kinetic modeling of Rasagiline mesylate from nanoscale solid lipid particles | |
| MX2007002375A (es) | Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad. | |
| Ramana | Preparation and In-vitro characterization of ethylcellulose coated pectin alginate microspheres of 5-fluorouracil for colon targeting | |
| JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
| Wang et al. | Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice | |
| KR100222306B1 (ko) | 닐바디핀 속효성 고형제제 및 이의 제조방법 | |
| Ogadah | Development of liquisolid systems for colon targeting | |
| EP4445899A1 (fr) | Formes posologiques à libération prolongée pour composés à faible solubilité et procédés de préparation de ces formes posologiques à libération prolongée | |
| Kumar et al. | Development of agglomerated crystals of olmesartan medoxomil by spherical crystalization technique for enhancing the micromeritic and solubility property | |
| Swain et al. | Formulation design, optimization, characterization and in vivo pharmacodynamic study of enteric coated mucoadhesive microcapsules of esomeprazole magnesium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |